← Back

Mednax Inc

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers and unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, maternal-fetal medicine nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. It also provides other pediatric subspecialty care, including pediatric intensivists, pediatric hospitalists, and pediatric surgeons; support services in other areas of hospitals comprising pediatric emergency room, labor and delivery area, and nursery and pediatric departments; a newborn hearing screening program. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Price · split & dividend adjusted

News & notes moving MD

MD▲

Pediatrix Medical beats Q2 earnings estimates on improved cash collections

Pediatrix Medical Group reported second-quarter 2026 adjusted earnings per share of 63 cents, beating the Zacks Consensus Estimate by 10.5% and rising 18.9% year over year. Net revenues increased 4.1% to $487.8 million, surpassing estimates by 2.2%, driven by improved cash collection activity and a favorable payor mix, along with contributions from recent acquisitions, though partly offset by lower patient volumes and higher operating costs. Adjusted EBITDA rose 4.4% to $76.4 million, and the company reaffirmed its full-year 2026 adjusted EBITDA guidance of $280 million to $300 million. During the first half of 2026, Pediatrix repurchased 2.8 million shares for $61.7 million, with $104.5 million remaining under its buyback program as of June 30.

MD ▲

Zacks Investment Research·20dRead more ▾

MD▼

StockStory flags Conagra, Laureate Education, and Pediatrix Medical as profitable but risky stocks

StockStory identifies Conagra, Laureate Education, and Pediatrix Medical Group as profitable companies facing headwinds that warrant caution. Conagra's trailing 12-month GAAP operating margin stands at 3.1%, with falling unit sales and a 13.8% annual decline in earnings per share over three years. Laureate Education posts a 24% operating margin but has seen disappointing student enrollment and earnings per share growth of just 4.2% annually over five years, trailing revenue gains. Pediatrix Medical Group's 11.3% operating margin is accompanied by a 1.7% annual sales decline over two years and flat revenue expectations for the next 12 months.

CAG ▼LAUR ▼MD ▼

StockStory·59dRead more ▾